The European Drugs Report 2026: trends and developments presents the latest analysis from the European Union Drugs Agency (EUDA) on the drugs situation in Europe. Addressing both the supply of illicit drugs and their consumption and related harms, it provides a comprehensive set of national data and key harm reduction interventions. Among the lessons: consumption patterns are evolving towards polyconsumption which has become the norm, where users combine substances, with an increasing risk of overdose. Faced with the extreme and rapid complexity of the market, characterized by a record availability of substances and the emergence of highly toxic synthetic products, caregivers find themselves facing major public health challenges.
Cannabis remains the most widely consumed drug in Europe. “ An estimated 15.4 million young European adults used the drug last year, and cannabis is now responsible for around a third of admissions for treatment related to drug use in Europe“, notes the report. Caregivers must be vigilant in the face of the unprecedented diversification of this market “ more and more complex“. Among the notable facts: Cannabis products adulterated with potent synthetic cannabinoids are available on the market; more recently, semi-synthetic cannabinoids have also become widespread. The availability of extracts and ingestible products with a high active ingredient content have been associated with visits to emergency rooms for acute toxicity. Potential risks are increased, and their assessment and implementation of appropriate treatment are complicated by the increasing availability of varied and potent cannabis products.“. The report emphasizes the need to “ strengthen the response capacities of health services in terms of management and treatment of risks linked to cannabis use« .
Polydrug use is now the norm, and the consumption of several psychoactive substances is common. This practice not only increases health risks, but also makes it difficult to implement effective interventions.
Ease of access to cocaine raises “health concerns”«
Cocaine is also one of the illicit drugs that causes the most consequences for public health. With an alarming level of availability (high purity rates at stable prices), she is ” a major cause of drug-related acute poisoning emergencies seen in sentinel hospitals (a network of around thirty university and general hospitals spread across Europe) and is frequently involved in deaths linked to drug use, accounting for around a quarter of cases according to the most recent data available for 20 countries“, underlines the report. “ The drug also looms large in treatment demands, with indicators suggesting that problems are getting worse rather than stable. Current evidence supports psychosocial interventions, including cognitive behavioral therapy and contingency management. However, the available data are not yet sufficient to recommend pharmacological treatment, although research is ongoing into different forms of agonist treatment. Integrated addiction treatment and mental health services are often lacking for users in this areaand it would be desirable to develop a tailor-made offer, even if this may prove difficult to implement« .
The fact that consumers are not always aware of the exact substances they are consuming presents new challenges for health and emergency services.
A health challenge
One of the priority challenges for healthcare professionals concerns the changing profile of opioids (1). While heroin remains responsible for a major share of drug-related mortality, the accelerated emergence of new, highly potent synthetic opioids poses a significant threat. In terms of public health, the 2026 report recommends a profound transformation of prevention strategies to cope with the extremely rapid evolution of the market, including the urgent deployment of drug checking services (drug checking), which make it possible to analyze substances and broadcast rapid alerts in the event of the presence of ultra-powerful molecules such as nitazenes (see the chapter “ New psychoactive substances« ).
To protect the most vulnerable populations, environmental and community prevention programs are necessary to delay the age of first consumption among young people. “ Whether implemented at the individual, family, school or community level, drug and crime prevention programs generally aim to build resilience and adaptive capacity, before problems arise or worsen, thereby enabling individuals and community structures to anticipate new challenges and respond effectively. This is of increasing importance as Europe’s drug problems evolve“. Finally, expanded access to naloxone (2) to counter overdoses and to diversified substitution treatments is recommended. The report above all calls for integrated risk reduction at each level of the care pathway.
1– The opioids are a large family of chemicals that interact with opioid receptors in the brain to block pain and provide relief or euphoria. They are divided into three main categories (natural, semi-synthetic and synthetic). In addition to their strong addictive power, they slow down the central nervous system. In high doses, they cause respiratory depression (the lungs stop working), which is the main cause of fatal overdoses.
2– Naloxone is the absolute emergency antidote in the event of an opioid overdose. It is a pure antagonist, which means that it acts as a shield: when administered, it will immediately dislodge the opioid from the receptors in the brain and attach itself there in its place. By blocking the action of the product, it instantly cancels its effects and restarts the person’s breathing in a few minutes, saving their life. It generally comes in the form of a nasal spray (very easy to use for loved ones or caregivers) or injection. According to the 2026 report, faced with new synthetic opioids (such as nitazenes), which are dozens of times more powerful than heroin, caregivers must often administer much higher or repeated doses of naloxone to successfully resuscitate the patient.
To find out more:
• European Union Drugs Agency (2026), European Drugs Report 2026: trends and developments, https://www.euda.europa.eu/publications/european-drug-report/2026_en
